260 related articles for article (PubMed ID: 31511442)
1. Rapid advances in research on and development of anticancer drugs in China.
Yao X; Du N; Hu S; Wang L; Gao J
Biosci Trends; 2019 Nov; 13(5):461-463. PubMed ID: 31511442
[TBL] [Abstract][Full Text] [Related]
2. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
3. [Progress on clinical trials of cancer drugs in China, 2019].
Huang HY; Wu DW; Wang HX; Wang J; Fan Q; Wang SH; Bai Y; Yu Y; Fang Y; Sun C; Fang H; Bai H; Wang X; Liu ZY; Jiang M; Liu Z; Wang XH; Li HY; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):127-132. PubMed ID: 32135647
[No Abstract] [Full Text] [Related]
4. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
Kawabata-Shoda E; Masuda S; Kimura H
J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
[TBL] [Abstract][Full Text] [Related]
5. [Progress on clinical trials of cancer drugs in China, 2020].
Wu DW; Huang HY; Tang Y; Wang HX; Wang J; Wang SH; Fang H; Yang XY; Li J; Wang X; Liu LJ; Yan Y; Wang Q; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):218-223. PubMed ID: 33601488
[No Abstract] [Full Text] [Related]
6. Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy.
Shibata S; Matsushita M; Saito Y; Suzuki T
Ther Innov Regul Sci; 2018 Nov; 52(6):718-723. PubMed ID: 29714569
[TBL] [Abstract][Full Text] [Related]
7. Novel anticancer drugs approved in 2020.
Li J; Wang R; Gao J
Drug Discov Ther; 2021; 15(1):44-47. PubMed ID: 33692282
[TBL] [Abstract][Full Text] [Related]
8. Research and development of mAb drugs in China: a look from policy perspectives.
Jiang R; Sun Y; Ung C; Dong X; Kong X; Hu Y; Shao R
Hum Vaccin Immunother; 2019; 15(11):2695-2705. PubMed ID: 31116629
[No Abstract] [Full Text] [Related]
9. Current clinical trials on breast cancer in China: A systematic literature review.
Fan Y; Xu B
Cancer; 2020 Aug; 126 Suppl 16():3811-3818. PubMed ID: 32710659
[TBL] [Abstract][Full Text] [Related]
10. [Considerations on Clinical Development and Regulatory of the Oversea License-in
Anti-tumor Drugs].
Zhao X; Hao R; Tong X; Zou L; Tang L; Zhang H; Xia L; Yang Z
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):448-451. PubMed ID: 35899440
[TBL] [Abstract][Full Text] [Related]
11. Challenges and Opportunities With Oncology Drug Development in China.
Bajaj G; Gupta M; Wang HH; Barrett JS; Tan M; Rupalla K; Bertz R; Sheng J
Clin Pharmacol Ther; 2019 Feb; 105(2):363-375. PubMed ID: 29328503
[TBL] [Abstract][Full Text] [Related]
12. Landscape of the clinical development of China innovative anti-lung cancer drugs.
Shi Y
Cancer Pathog Ther; 2023 Jan; 1(1):67-75. PubMed ID: 38328605
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Drug Development and Regulatory Science in China.
Chen J; Zhao N
Ther Innov Regul Sci; 2018 Nov; 52(6):739-750. PubMed ID: 29714583
[TBL] [Abstract][Full Text] [Related]
14. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
[TBL] [Abstract][Full Text] [Related]
15. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis.
Luo X; Du X; Huang L; Guo Q; Tan R; Zhou Y; Li Z; Xue X; Li T; Le K; Qian F; Chow SC; Yang Y
Lancet Reg Health West Pac; 2023 Mar; 32():100670. PubMed ID: 36785854
[TBL] [Abstract][Full Text] [Related]
16. [Future directions of anticancer drug development in Japan].
Akaza H; Kawai K; Tsuruo T; Tsukagoshi S; Aiba K; Shimada Y; Kakeji Y; Ishikawa H; Ikeda T; Nakamura S; Tamura T; Yamamoto N; Isonishi S; Hinotsu S; Hirose M; Katsura J
Gan To Kagaku Ryoho; 2008 Feb; 35(2):351-60. PubMed ID: 18281781
[TBL] [Abstract][Full Text] [Related]
17. Drug policy in China. Transformations, current status and future prospects.
Liu X; Li S
Pharmacoeconomics; 1997 Jul; 12(1):1-9. PubMed ID: 10169383
[TBL] [Abstract][Full Text] [Related]
18. Accelerating the integration of China into the global development of innovative anticancer drugs.
Huang H; Wu D; Miao H; Tang Y; Liu C; Fang H; Meng X; Wang S; Zhu Q; Wang X; Du J; Yang Z; Li N; Xu B; He J
Lancet Oncol; 2022 Nov; 23(11):e515-e520. PubMed ID: 36328025
[TBL] [Abstract][Full Text] [Related]
19. A systematic analysis of FDA-approved anticancer drugs.
Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
[TBL] [Abstract][Full Text] [Related]
20. Current situation and future usage of anticancer drug databases.
Wang H; Yin Y; Wang P; Xiong C; Huang L; Li S; Li X; Fu L
Apoptosis; 2016 Jul; 21(7):778-94. PubMed ID: 27193464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]